Financial Performance - For the six months ended June 30, 2019, the group achieved a consolidated revenue of RMB 200,755,549, representing a year-on-year increase of 13.92% compared to RMB 176,221,094 for the same period in 2018[6] - The consolidated gross profit for the same period was RMB 25,449,134, which reflects a year-on-year decrease of 10.74% from RMB 28,510,763 in 2018[6] - The loss attributable to equity holders of the company was RMB 6,835,079, a reduction of 16.50% compared to a loss of RMB 8,185,599 in the previous year[6] - The basic loss per share for the period was RMB 0.361, compared to RMB 0.467 for the same period in 2018[6] - The company reported a net loss before tax of RMB 6,047,281, compared to a loss of RMB 5,412,772 in the previous year, highlighting ongoing financial challenges[7] - The total revenue for the six months ended June 30, 2019, was RMB 200,751,856, representing a year-on-year increase of 13.92% compared to RMB 176,221,094 for the same period in 2018[39] - The comprehensive gross profit for the same period was RMB 25,449,134, which is a year-on-year decrease of 10.74% from RMB 28,510,763 in 2018, resulting in a gross profit margin of 12.67%, down 3.50% from 16.18% in 2018[39] Assets and Liabilities - The total assets of the company as of June 30, 2019, amounted to RMB 465,702,878, an increase from RMB 448,979,504 as of December 31, 2018[9] - Current assets increased to RMB 311,724,865 from RMB 293,901,494 in the previous year, driven by an increase in trade receivables[9] - Total current liabilities increased to RMB 175,442,951 as of June 30, 2019, from RMB 157,311,873 as of December 31, 2018, reflecting an increase of approximately 11.5%[10] - The company’s total equity attributable to owners decreased to RMB 265,461,060 as of June 30, 2019, from RMB 273,005,905 as of December 31, 2018, reflecting a decline of approximately 2.8%[10] - The total liabilities decreased from RMB 64,385,639 as of December 31, 2018, to RMB 46,543,013 as of June 30, 2019[30] - The total liabilities were approximately RMB 175,442,951, compared to RMB 157,311,873 as of December 31, 2018, resulting in a debt-to-asset ratio of 0.38[45] Cash Flow and Investments - Net cash used in operating activities for the six months ended June 30, 2019, was RMB (24,821,594), compared to RMB (32,883,274) in the same period of 2018, indicating an improvement of about 24%[12] - The company’s investment cash outflow for the six months ended June 30, 2019, was RMB (519,262), compared to RMB (4,529,723) in the same period of 2018, indicating a significant reduction in investment spending[12] - Cash and bank balances decreased to RMB 15,288,638 as of June 30, 2019, from RMB 52,979,680 as of June 30, 2018, representing a decline of approximately 71%[12] Operational Highlights - Research and development expenses for the period were RMB 20,445,159, compared to RMB 19,239,128 in the previous year, indicating a focus on innovation[7] - Sales and distribution costs decreased by 19.43% to RMB 9,636,063.96 for the six months ended June 30, 2019, compared to RMB 11,960,597 in the previous year[40] - Research and administrative expenses increased by 6.27% to RMB 20,445,160 for the same period, up from RMB 19,239,128 in 2018[41] - Interest expenses on bank loans for the six months ended June 30, 2019, were RMB 1,685,338, a decrease from RMB 1,827,771 in the same period of 2018, showing a reduction of about 7.7%[14] Shareholder Information - As of June 30, 2019, major shareholders included Tianjin TEDA International Entrepreneurship Center with a 9.63% stake and Shenzhen Xiangyong Investment Co., Ltd. with a 9.50% stake[55] - The company’s board members and supervisors collectively hold 300,000,000 shares, representing 15.83% of the issued share capital[52] - The weighted average number of ordinary shares for the calculation of basic loss per share was 1,894,500,000 for the six months ended June 30, 2019[22] Corporate Governance - The board of directors has complied with all corporate governance code provisions except for the separation of roles between the chairman and the CEO until February 1, 2019[65] - The audit committee reviewed the interim results and report for the six months ended June 30, 2019[60] - The company has maintained effective internal controls and risk assessment processes[59] Strategic Initiatives - The company is actively seeking partners and expanding its market for its EEG detection system, which has faced delays due to regulatory challenges and market conditions[37] - The company signed a strategic cooperation agreement with Almage Group for Alzheimer's care and nursing home management on March 30, 2019[37] - The company is developing a healthcare and elderly care industry holding platform to enhance its core competitiveness and create a new profit growth point[50] - The company aims to enhance its compound fertilizer business by ensuring product quality and expanding its customer base amid a stable supply-demand situation in the fertilizer industry[49] - The aging population in China has prompted the government to implement policies to support the development of the elderly care service industry, which the company is actively engaging in[50] Dividend and Share Transactions - The company did not recommend the payment of dividends for the six months ended June 30, 2019[6] - The company did not declare any interim dividend for the six months ended June 30, 2019[67] - There were no new share option schemes approved during the period ended June 30, 2019[61] - The company did not repurchase any of its shares during the review period[63] - There were no securities transactions by directors that violated the trading code during the review period[64]

法 天 津 泰 建 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳 的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關 天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本報告的 ...

Company Overview - The registered capital of Tianjin TEDA Biomedical Engineering Company Limited is RMB 189.045 million[4]. - Tianjin TEDA Biomedical Engineering Company Limited was officially listed on the Hong Kong GEM on June 18, 2002, under stock code 8189[4]. - The company operates in two main business areas: biological composite fertilizers and elderly care services, focusing on the elderly population with disabilities and dementia[4]. Business Operations - The biological composite fertilizer business includes a range of products aimed at promoting balanced growth of various crops[4]. - The company has completed acquisitions to exclusively own EEG quantitative detection and analysis technology, collaborating with medical institutions for accurate diagnosis of neurological and psychological diseases[4]. - The company is involved in the operation and management of elderly care facilities across the country, integrating resources and providing management consulting services[4]. - The company has a 100% ownership in Guangdong Welfare Dragon Composite Fertilizer Co., Ltd., which focuses on R&D, production, and sales of biological composite fertilizers[5]. - The company also holds a 51% stake in Shandong Haides Fertilizer Co., Ltd., which is engaged in similar fertilizer activities[5]. - The company has established a research institute for soil conditioning and restoration, focusing on regional soil resource management[5]. - The company is expanding its elderly care services and health management through various subsidiaries, including Beijing Hongdi Elderly Investment Management Co., Ltd.[5]. Financial Performance - The company reported a revenue of RMB 351,898,000 for the year ended December 31, 2018, representing a year-on-year decrease of 6.39%[18]. - The gross profit for 2018 was RMB 1,707,000, a significant decline of 96.79% compared to the previous year[18]. - The gross margin for 2018 was 0.49%, down from the previous year's margin, indicating a challenging operational environment[18]. - The attributable loss to shareholders for 2018 was RMB 177,680,000, with a loss per share of RMB 9.58, an increase of 1,068.29% from the previous year's loss per share of RMB 0.82[18]. - Total assets as of December 31, 2018, were RMB 448,980,000, a decrease from RMB 707,878,000 in 2017[10]. - Total liabilities increased to RMB 157,312,000 in 2018 from RMB 133,078,000 in 2017[10]. - The total revenue for the year ended December 31, 2018, was RMB 351,897,658, a decrease of 6.39% compared to RMB 375,906,530 in 2017[29]. - The comprehensive gross profit for the year was RMB 1,706,855, with a gross margin of 0.49%, down from 14.15% in the previous year[29]. - The impairment loss on intangible assets recognized for the year was RMB 227,361,866, attributed to changes in the Chinese market and business strategy[31]. - Other income and net losses for the year amounted to RMB 3,680,687, a decrease from RMB 5,377,946 in 2017[34]. - Research and development expenses for the year were RMB 11,667,239, an increase of 25.53% from RMB 9,294,266 in 2017[34]. - The administrative expenses for the year were RMB 32,195,141, a decrease of 11.13% from RMB 36,227,996 in the previous year[34]. Research and Development - The company has strengthened its R&D efforts in collaboration with the Chinese Academy of Agricultural Sciences to develop new fertilizer products[16]. - The company has launched a new brainwave detection service and established a new detection point in Xiamen[16]. - The company has developed new fertilizer products, including active shell chitosan soluble fertilizer and microbial fertilizers, which have received widespread recognition from farmers[24]. - The company has increased R&D efforts in organic fertilizers, with microbial fertilizers currently accounting for only about 7% of total fertilizer usage in China, compared to nearly 50% in developed countries[24]. - The company is committed to enhancing its core competitiveness through a technology innovation system that integrates market orientation and academic research[22]. - The company has established strategic collaborations with leading research institutions to develop new fertilizer products that meet green agricultural needs[24]. Elderly Care Services - The company won 8 projects in the Shanghai public bidding for elderly care services, aiming to provide rehabilitation and group therapy for 1,000 elderly individuals[16]. - The company aims to develop a professional elderly care industry chain in collaboration with top institutions in Europe, focusing on care for the elderly with disabilities and dementia[22]. - The company’s elderly care services are positioned to serve a wide demographic, including youth and the elderly, addressing various health management needs[25]. - The company has established a joint venture in Shandong to promote the "Shui Fa Rui Fu Elderly Care" brand and provide consulting services in elderly care management[29]. - The company is actively involved in international cooperation in the elderly care sector, partnering with French organizations to enhance service quality and operational standards[98]. Corporate Governance - The company is focusing on enhancing its corporate governance and risk management systems in compliance with GEM listing rules[19]. - The board of directors and management have been deemed to operate in compliance with laws and regulations, ensuring the protection of shareholder interests[68]. - The supervisory board held four meetings during the reporting period to review financial reports and ensure compliance with corporate governance[67]. - The company aims to enhance its internal control systems and governance structure in the upcoming year[70]. - The company has a strong management team with diverse backgrounds in finance, law, and healthcare, enhancing its operational capabilities[93][94][98]. - The board consists of nine members, including three executive directors, three non-executive directors, and three independent non-executive directors, ensuring compliance with GEM listing rules[124]. - The independent non-executive directors have confirmed their independence according to GEM listing rules, ensuring a balanced approach to shareholder interests[131]. Environmental Responsibility - The group focuses on environmental protection, with no significant pollution issues in its operations related to elderly care and health services[174]. - The company has implemented effective waste management practices, ensuring all solid waste is comprehensively utilized[177]. - The company has implemented advanced production processes, including high tower granulation and drum granulation, to minimize energy consumption and pollutant generation[186]. - Compliance with various environmental standards includes COD levels not exceeding 350 mg/L and ammonia levels not exceeding 20 mg/L in wastewater treatment agreements[188]. - The company plans to continue enhancing its environmental protection measures and resource utilization efficiency in future operations[196].